Infectious Diseases

The new data, published in The Lancet, showed that nirsevimab substantially reduced RSV hospitalizations.

ICD-10 accuracy varied by age of the patient, influenza season definition, time between onset and testing, and clinical setting.

New cohort analyses observe a statistically raised risk of myocarditis, pericarditis and seizures among certain age groups, though the data do not go against FDA recommendations.

Cohort analysis shows the rate of RSV hospitalizations among children up to 5 years old skyrocketed in 2021—and then nearly doubled again in 2022—compared to pre-pandemic rates.

The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.

New data demonstrates protection against new variants.

Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, shares her thoughts on the latest issue of Contemporary Pediatrics.

The investigators concluded that age-related risk differences "highlight the necessity for tailored strategies, improving understanding of and treatment development for RVIs."

An increase in measles cases, 58 confirmed to the CDC as of March 14, 2024, has prompted the agency to send a health advisory alert to health care providers.

An intervention applied at family care practices shows benefit to tailoring education to both clinicians and medical assistants.

Tina Tan, MD, FAAP, FIDSA, FPIDS, tells Contemporary Pediatrics, “This is not new and demonstrates what is known, in that if vaccination rates do not stay at a level that is protective, outbreaks of vaccine preventable diseases will occur.”

A pediatric health system discontinues MRSA contact precautions with sustained infection control success, supporting broader consideration while emphasizing the importance of horizontal prevention measures.

A discussion of the intense 2023 RSV season, approved treatment tools, and an outlook for 2024.

Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses vaccine hesitancy and hopes to increase vaccination for preventable diseases in 2024.

The unprecedented demand for nirsevimab-alip has resulted in a dramatic uptake in production of this RSV vaccine.

In the second installment of RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.

Steven Selbst, MD, provides a quick update on what he has noticed in his hospital when it comes to RSV-associated emergency department visits and how they compare to this time last year, during the "tripledemic." This interview was conducted at the 2023 American Academy of Pediatrics National Conference and Exhibition in Washington DC.

Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.

A sneak peek at some of the most exciting sessions at this year's American Academy of Pediatrics national conference.

Parents who reported the stigmatizing belief “My child is not having sex” were much more likely to rely on health care providers as a source of information than parents who did not report this belief.

For this highly infectious disease, a thoughtful and comprehensive approach to care and treatment are a necessity.

At IDWeek 2023, a presentation sharing the latest news in RSV vaccines.

At IDWeek 2023, a session on how increased rates of the HPV vaccine have resulted in a decline in certain conditions and disease states.

At IDWeek 2023, a presentation on the challenges to the diagnosis and management of VAIs in children.

At IDWeek 2023, updates on CLABSIs in the pediatric population.

At IDWeek 2023, a presenter shares his own studies on the impact of viral effects after infection.

At IDWeek 2023, a presenter discusses the future of infection prevention from organ transplants in children.

At IDWeek 2023, several authors share a study on mother-infant pairs, evaluating for differences in rates of influenza infections in infants.